You just read:

OncoQuest Announces Enrollment of First Patient in Phase 1/2 Clinical Study Using Combination of Oregovomab with Checkpoint Inhibitor Nivolumab in Recurrent Ovarian Cancer

News provided by

Quest PharmaTech Inc.

May 09, 2017, 07:00 ET